Audit Commission
|
British Medical Association
|
Canadian Agency for Drugs and Technologies in Health (CADTH)
|
Care Quality Commission (CQC)
|
Centre for Mental Health
|
Clinical Knowledge Summaries (PRODIGY) / SCHINN
|
Cochrane Collaboration
 New systematic reviews:
|
Department of Health (DH)
|
European Medicines Agency (EMA)
 CHMP revised EPARs started on:
- Olazax, Olanzapine, Revision: 2, Authorised
- Pramipexole Teva, Pramipexole, Revision: 8, Authorised
- Sycrest, asenapine Revision: 1, Authorised
- Sycrest, Asenapine, Revision: 0, Authorised
- Xeplion, Paliperidone, Revision: 0, Authorised
- Zypadhera, Olanzapine, Revision: 3, Authorised
- Zyprexa, Olanzapine, Revision: 25, Authorised
Pending EC decision :
- Rivastigmine Actavis, rivastigmine
Referrals:
- Article 31 referrals, Valproate, Valproic acid/valproate
Opinion/decision:
- Paediatric Investigation Plan (PIP): Exelon, Rivastigmine
|
Food and Drug Administration (FDA)
Approvals and tentative approvals :
|
General Medical Council
|
Health Technology Assessment (HTA)
|
InfoPOEMs |
Joseph Rowntree Foundation (JRF)
|
Kings Fund
 Publications:
|
Medicines and Healthcare products Regulatory Agency (MHRA)
|
Mental Health Foundation (MHF)
|
MIND
|
National electronic Library for Medicines (NeLM)
|
National Institute for Health and Clinical Excellence (NICE)
 Publications:
|
National Mental Health Development Unit (NMHDU):
|
National Prescribing Centre (NPC)
|
National Treatment Agency for Substance Misuse
|
NHS Alliance
|
NHS Choices |
NHS Confederation |
NHS Information Centre
|
NIHR Service Delivery and Organisation programme
|
Office for National Statistics (ONS)
|
Rethink |
Royal College of General Practitioners (RCGP)
|
Royal College of Psychiatrists (RCPsych)
|
Royal Pharmaceutical Society (RPS)
|
Scottish Medicines Consortium (SMC)
|
University of Oxford Centre for Suicide Research (CSR)
|